Dr Michel Dione
Scientist - Animal Health, Animal and Human Health
International Livestock Research Institute
Pest des Petits Ruminants (PPR) is a disease with huge economic, food security and livelihood impacts. It is caused by a is a highly contagious, acute viral disease that primarily effects domestic small ruminants. The presence of the virus has been confirmed in Asia, the Middle East and Africa, and is spreading to new countries, affecting an increasing number of small ruminant populations and livelihoods. The disease can be controlled by disinfection of on-farm material and structures, safe disposal of dead animals, and slaughtering of sick animals. The main control method of PPR is vaccination. Many vaccines are commercially available and have shown to be effective for at least three years post-vaccination. All animals must be vaccinated. However, most of the currently available vaccines require a strict cold chain for to offer good immunity after vaccination, yet there is a lack of power particularly in remote areas of developing countries. There is a homologous live attenuated vaccine that protects small ruminant against PPR to control losses. However, this vaccine requires the maintenance of cold chain which is a serious challenge in remote areas with no access to electricity or where recurrent power failures make it difficult to keep vaccines cold. This situation is problematic and is a major cause of failure to most vaccination programs especially in countries where ambient temperatures are high.
ILRI-Feed the Future Mali Livestock Technology Scaling Program supports the Central Veterinary Laboratory (LCV) of Bamako in the production and deployment of 2 thermotolerant PPR vaccines with the technical support from Hester Biosciences Ltd. The proposed vaccines (Xerovac and ILRI protocols) are considerably stable at ambient temperatures, which is useful in hot countries and in remote areas. The LCV vaccine was used as a control vaccine. The program developed two thermotolerant PPR vaccines that use the Nigeria 75/1 strain: Xerovac vaccine which is based on an LCV protocol but has never been produced for marketing yet – with thermostability for at least 14 days at 40°C and 10 days at 45°C; and ILRI protocol-based vaccine which was derived from the protocol developed by ILRI and transferred to the LCV/Mali, stable and viable up to seven days at 40°C. Both vaccines met the FAO and OIE standards (which is at least 25°C for 10 days or 40°C for 2 days) which is an advantage for hot climate countries in remote areas.
Enough thermostability of PPR vaccine will enable its use without or limited cold chain will greatly facilitate the delivery of vaccination. This will remove the need for heavy cold chain maintenance and will therefore have a significant impact on reducing costs of PPR control programs. It is also expected that vaccination campaigns will be more effective in terms of immunity gains against PPR as failure due to breakdown in cold-chain maintenance would be reduced. This will translate into improved productivity. The large-scale use of the new thermostable vaccine will have a great impact on the control of PPR in Africa and in the world.
Sorry, no records were found. Please adjust your search criteria and try again.
Sorry, unable to load the Maps API.